TY - JOUR

T1 - Treatment of Ebola Virus Disease: From Serotherapy to the Use of Monoclonal Antibodies

AU - Shcherbakov, Dmitriy N.

AU - Isaeva, Anastasiya A.

AU - Mustaev, Egor A.

N1 - This research was funded by the Ministry of Science and Higher Education of the Russian Federation (agreement # 075-15-2019-1665).

PY - 2025/3/5

Y1 - 2025/3/5

N2 - Ebola virus disease (EVD) is an acute illness with a high-case fatality rate (CFR) caused by an RNA virus belonging to the Filoviridae family. Over the past 50 years, regular EVD outbreaks have been reported. The West African EVD outbreak of 2013–2016 proved to be significantly more widespread and complex than previous ones, resulting in approximately 11,000 deaths. A coordinated international effort was required to bring the outbreak under control. One of the main challenges faced by clinicians and researchers combating EVD was the absence of vaccines and preventive treatments. Only recently have efforts led to the development of effective therapeutic options. Among these, monoclonal antibody-based drugs have emerged as the most promising agents for the urgent treatment of EVD. This article aims to review the key milestones in the development of antibody-based therapies for EVD, tracing the journey from the use of convalescent serum to the creation of effective monoclonal antibody-based drugs and their combinations.

AB - Ebola virus disease (EVD) is an acute illness with a high-case fatality rate (CFR) caused by an RNA virus belonging to the Filoviridae family. Over the past 50 years, regular EVD outbreaks have been reported. The West African EVD outbreak of 2013–2016 proved to be significantly more widespread and complex than previous ones, resulting in approximately 11,000 deaths. A coordinated international effort was required to bring the outbreak under control. One of the main challenges faced by clinicians and researchers combating EVD was the absence of vaccines and preventive treatments. Only recently have efforts led to the development of effective therapeutic options. Among these, monoclonal antibody-based drugs have emerged as the most promising agents for the urgent treatment of EVD. This article aims to review the key milestones in the development of antibody-based therapies for EVD, tracing the journey from the use of convalescent serum to the creation of effective monoclonal antibody-based drugs and their combinations.

KW - Ebola virus disease

KW - filoviruses

KW - monoclonal antibodies

KW - neutralizing antibodies

KW - passive immunization

UR - https://www.mendeley.com/catalogue/f04580dc-5924-3785-83f7-2f02443766e0/

UR - https://www.scopus.com/record/display.uri?eid=2-s2.0-105001155395&origin=inward&txGid=c01c1666d85deaefa0d696814a87f53b

U2 - 10.3390/antib14010022

DO - 10.3390/antib14010022

M3 - Article

C2 - 40136471

VL - 14

JO - Antibodies

JF - Antibodies

SN - 2073-4468

IS - 1

M1 - 22

ER -